Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

Still in the game, but just barely, is Basel–based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing. Table 1 Selected MS therapies in ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that ...

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...

Medically reviewed by Gurdeep S. Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD Even though multiple sclerosis ...